Thomas F. Pajak - Researcher Profile

Publications

5 shown

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data

Stefan Michiels , Aurélie Le Maître , Marc Buyse +9 more

2009 The Lancet Oncology 161 citations

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)

James D. Cox , JoAnn Stetz , Thomas F. Pajak

1995 International Journal of Radiation On... 4740 citations

A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003

Karen K. Fu , Thomas F. Pajak , Andy Trotti +7 more

2000 International Journal of Radiation On... 1355 citations

Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis

Jean Bourhis , Jens Overgaard , Hélène Audry +17 more

2006 The Lancet 1065 citations

Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the radiation therapy oncology group study 81-17

Víctor A. Marcial , Thomas F. Pajak , Mohammed Mohiuddin +7 more

One hundred twenty-four eligible patients with advanced mucosal squamous cell carcinoma of the head and neck were entered into a pilot study of concomitant cisplatin (100 mg/m2 ...

1990 Cancer 191 citations

Frequent Co-Authors

Researcher Info

h-index: 5
Publications: 5
Citations: 7,512
Institution: RTOG Foundation

External Links

Google Scholar

Impact Metrics

h-index 5

h-index: Number of publications with at least h citations each.